Browse: Departments   Dates   Agencies  

DOCUMENT ID: [60Day-07-0527]

NOTICE: NOTICES

SUBJECT CATEGORY: Proposed Data Collections Submitted for Public Comment and Recommendations

DOCUMENT SUMMARY:

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046394766 or send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MSD74, Atlanta, GA 30333 or send an email to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project

Human Exposure to Cyanobacterial (bluegreen algal) Toxins in Drinking Water: Risk of Exposure to Microcystin from Public Water Systems (OMB No. 09200527)ExtensionNational Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC). Background and Brief Description

Cyanobacteria (bluegreen algae) can be found in terrestrial, fresh, brackish, or marine water environments. Some species of cyanobacteria produce toxins that may cause acute or chronic illnesses (including neurotoxicity, hepatotoxicity, and skin irritation) in humans and animals (including other mammals, fish, and birds). A number of human health effects, including gastroenteritis, respiratory effects, skin
[[Page 75967]]
irritations, allergic responses, and liver damage, are associated with the ingestion of or contact with water containing cyanobacterial blooms. Although the balance of evidence, in conjunction with data from laboratory animal research, suggests that cyanobacterial toxins are responsible for a range of human health effects, there have been few epidemiologic studies of this association.

CDC plans to recruit 100 people whose tap water comes from a source with a current cyanobaterial bloom (i.e., M. aeruginosa) and who report drinking unfiltered tap water. We also plan to recruit 100 people who report drinking unfiltered tap water but whose tap water source is groundwater that is not contaminated with cyanobacteria. This population will serve as our referent population for the analysis of microcystins in blood and for the clinical assays. We will administer a questionnaire and collect blood samples from all study participants. Blood samples will be analyzed using a newly developed molecular assay for levels of microcystins, the hepatotoxin produced by Micocystis aeruginosa. We also will analyze blood samples for levels of liver enzymes (a biological marker of hepatotoxicity) and for a number of clinical parameters including hepatitis infection (a potential confounder in our study). We will evaluate whether we can (1) Detect low levels of microcystins (< 10 ng/ml of blood), in the blood of people who are exposed to very low levels of this toxin in their drinking water and (2) Utilize clinical endpoints such as blood liver enzyme levels as biomarkers of exposure and biological effect, and (3) Compare the analytical results for the exposed population with the results from the referent population.

CDC is working with a group of utility companies that are interested in the project and plan to discuss implementation logistics early in 2007. There are no costs to respondents except their time to participate in the survey.
Estimated Annualized Burden Hours No. of Average burden Respondents No. of responses per per response Total Burden respondents respondent (in hours) (in hours) Telephone Contact............................... 300 1 10/60 50 Interview....................................... 200 1 1 200 Blood Samples Collection........................ 200 1 20/60 67 Tap Water Sample Collection..................... 200 1 30/60 100

Total....................................... .............. .............. .............. 417

Dated: December 13, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E621584 Filed 121806; 8:45 am]
BILLING CODE 416318P

SUMMARY: Agency information collection activities; proposals, submissions, and approvals,

DOCUMENT BODY 2:

In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 for opportunity for public comment on proposed data collection projects, the Centers for Disease Control and Prevention (CDC) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the data collection plans and instruments, call 4046394766 or send comments to Seleda Perryman, CDC Assistant Reports Clearance Officer, 1600 Clifton Road, MSD74, Atlanta, GA 30333 or send an email to omb@cdc.gov.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Written comments should be received within 60 days of this notice.

Proposed Project

Human Exposure to Cyanobacterial (bluegreen algal) Toxins in Drinking Water: Risk of Exposure to Microcystin from Public Water Systems (OMB No. 09200527)ExtensionNational Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC). Background and Brief Description

Cyanobacteria (bluegreen algae) can be found in terrestrial, fresh, brackish, or marine water environments. Some species of cyanobacteria produce toxins that may cause acute or chronic illnesses (including neurotoxicity, hepatotoxicity, and skin irritation) in humans and animals (including other mammals, fish, and birds). A number of human health effects, including gastroenteritis, respiratory effects, skin
[[Page 75967]]
irritations, allergic responses, and liver damage, are associated with the ingestion of or contact with water containing cyanobacterial blooms. Although the balance of evidence, in conjunction with data from laboratory animal research, suggests that cyanobacterial toxins are responsible for a range of human health effects, there have been few epidemiologic studies of this association.

CDC plans to recruit 100 people whose tap water comes from a source with a current cyanobaterial bloom (i.e., M. aeruginosa) and who report drinking unfiltered tap water. We also plan to recruit 100 people who report drinking unfiltered tap water but whose tap water source is groundwater that is not contaminated with cyanobacteria. This population will serve as our referent population for the analysis of microcystins in blood and for the clinical assays. We will administer a questionnaire and collect blood samples from all study participants. Blood samples will be analyzed using a newly developed molecular assay for levels of microcystins, the hepatotoxin produced by Micocystis aeruginosa. We also will analyze blood samples for levels of liver enzymes (a biological marker of hepatotoxicity) and for a number of clinical parameters including hepatitis infection (a potential confounder in our study). We will evaluate whether we can (1) Detect low levels of microcystins (< 10 ng/ml of blood), in the blood of people who are exposed to very low levels of this toxin in their drinking water and (2) Utilize clinical endpoints such as blood liver enzyme levels as biomarkers of exposure and biological effect, and (3) Compare the analytical results for the exposed population with the results from the referent population.

CDC is working with a group of utility companies that are interested in the project and plan to discuss implementation logistics early in 2007. There are no costs to respondents except their time to participate in the survey.
Estimated Annualized Burden Hours No. of Average burden Respondents No. of responses per per response Total Burden respondents respondent (in hours) (in hours) Telephone Contact............................... 300 1 10/60 50 Interview....................................... 200 1 1 200 Blood Samples Collection........................ 200 1 20/60 67 Tap Water Sample Collection..................... 200 1 30/60 100

Total....................................... .............. .............. .............. 417

Dated: December 13, 2006.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. E621584 Filed 121806; 8:45 am]
BILLING CODE 416318P